Home > Haematology > EHA 2020 > Nivolumab/brentuximab vedotin in R/R HL: good CMR rates

Nivolumab/brentuximab vedotin in R/R HL: good CMR rates

Early data featured high rates of complete metabolic response (CMR) before consolidation with high-dose chemotherapy (HDCT)/auto-HCT in the standard-risk patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL).

Prof. Christine Mauz-Körholz (Justus-Liebig-Universität Gießen, Germany) presented the results of the Checkmate 744 trial [1], which tested a new therapy in children, adolescents, and young adults 5–30 years old (CAYA) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL), particularly those who do not achieve complete metabolic response (CMR) before autologous haematopoietic cell transplantation (auto-HCT). First salvage therapy with nivolumab + brentuximab vedotin (BV) has shown a CMR rate of 67% and a 2-year progression-free survival (PFS) rate of 79% in adults with R/R cHL, but it is unknown how this translates to CAYA. CheckMate 744 is an ongoing phase 2 study ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on